A groundbreaking medication, retatrutide, is sparking growing attention in the UK as a potential solution for obesity. Formulated by the manufacturer, this medicine merges the properties of two GLP-1 receptor agonists and an GIP receptor agonist, aiming to more effectively control hunger and improve calorie burning. Initial research have demonstrat